ArticleMolecular biology reports2012
Neuroprotective properties of aucubin in diabetic rats and diabetic encephalopathy rats.
Article in Molecular biology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- Aucubin mitigates the elevation of microglial aerobic glycolysis and inflammation in diabetic neuropathic painWorld journal of diabetes · 2025Article
- Scientometric analysis and historical review of diabetic encephalopathy research: Trends and hotspots (2004-2023).World journal of diabetes · 2025Article
- Review
- Neurotrophic Natural Products.Progress in the chemistry of organic natural products · 2024Article
- The activation of spliced X-box binding protein 1 by isorhynchophylline therapy improves diabetic encephalopathy.Cell biology and toxicology · 2023Article
- Characteristics, Isolation Methods, and Biological Properties of Aucubin.Molecules (Basel, Switzerland) · 2023Review
- Aucubin protects against retinal ganglion cell injury in diabetic rats via inhibition of the p38MAPK pathway.American journal of translational research · 2023Article
- Research progress on the protective effects of aucubin in neurological diseases.Pharmaceutical biology · 2022Review
- Iridoid glycoside Aucubin protects against nonylphenol-induced testicular damage in male rats via modulation of steroidogenic and apoptotic signaling.Scientific reports · 2022Article
- Aucubin Exerts Anticancer Activity in Breast Cancer and Regulates Intestinal Microbiota.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Aucubin alleviates oxidative stress and inflammation via Nrf2-mediated signaling activity in experimental traumatic brain injury.Journal of neuroinflammation · 2020Article
- Medicinal plants and their isolated phytochemicals for the management of chemotherapy-induced neuropathy: therapeutic targets and clinical perspective.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019Review
- Aucubin Alleviates Seizures Activity in Li-Pilocarpine-Induced Epileptic Mice: Involvement of Inhibition of Neuroinflammation and Regulation of Neurotransmission.Neurochemical research · 2019Article
- Aucubin Promotes Differentiation of Neural Precursor Cells into GABAergic Neurons.Experimental neurobiology · 2018Article
- Aucubin Protects against Myocardial Infarction-Induced Cardiac Remodeling via nNOS/NO-Regulated Oxidative Stress.Oxidative medicine and cellular longevity · 2018Article
- Endoplasmic reticulum stress-induced neuronal inflammatory response and apoptosis likely plays a key role in the development of diabetic encephalopathy.Oncotarget · 2016Article
- A new furofuran lignan diglycoside and other secondary metabolites from the antidepressant extract of Castilleja tenuiflora Benth.Molecules (Basel, Switzerland) · 2015Article
- Phytochemical profile ofPhytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2015Review
- Aucubin promotes neurite outgrowth in neural stem cells and axonal regeneration in sciatic nerves.Experimental neurobiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we determined the neuroprotective effect of aucubin on diabetes and diabetic encephalopathy. With the exception of the control group, all rats received intraperitoneal injections of streptozotocin (STZ; 60 mg/kg) to induce type 1 diabetes mellitus (DM). Aucubin (1, 5, 10 mg/kg ip) was used after induction of DM (immediately) and diabetic encephalopathy (65 days after the induction of diabetes). The diabetic encephalopathy treatment groups were divided into short-term and long-term treatment groups. Treatment responses to all parameters were examined (body weight, plasma glucose, Y-maze error rates and proportion of apoptotic cells). In diabetic rats, aucubin controlled blood glucose levels effectively, prevented complications, and improved the quality of life of diabetic rats. In diabetic encephalopathy, aucubin significantly rescued neurons in the hippocampal CA1 subfield and reduced working errors during behavioral testing. The significant neuroprotective effect of aucubin could be seen not only in the short term (15 days) but also in the long term (45 days), which was a highly encouraging finding. These data suggest that aucubin may be a potential neuroprotective agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.